<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="abstract" xml:lang="en"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Pediatr Rheumatol Online J</journal-id><journal-id journal-id-type="iso-abbrev">Pediatr Rheumatol Online J</journal-id><journal-title-group><journal-title>Pediatric Rheumatology Online Journal</journal-title></journal-title-group><issn pub-type="epub">1546-0096</issn><publisher><publisher-name>BioMed Central</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmc">4190936</article-id><article-id pub-id-type="publisher-id">1546-0096-12-S1-P130</article-id><article-id pub-id-type="doi">10.1186/1546-0096-12-S1-P130</article-id><article-categories><subj-group subj-group-type="heading"><subject>Poster Presentation</subject></subj-group></article-categories><title-group><article-title>Evaluation of the disease course of Italian children with juvenile idiopathic arthritis treated with etanercept: preliminary results in 772 patients</article-title></title-group><contrib-group><contrib contrib-type="author" id="A1"><name><surname>Verazza</surname><given-names>Sara</given-names></name><xref ref-type="aff" rid="I1">1</xref></contrib><contrib contrib-type="author" corresp="yes" id="A2"><name><surname>Consolaro</surname><given-names>Alessandro</given-names></name><xref ref-type="aff" rid="I1">1</xref></contrib><contrib contrib-type="author" id="A3"><name><surname>Robbiano</surname><given-names>Cristina</given-names></name><xref ref-type="aff" rid="I1">1</xref></contrib><contrib contrib-type="author" id="A4"><name><surname>Insalaco</surname><given-names>Antonella</given-names></name><xref ref-type="aff" rid="I2">2</xref></contrib><contrib contrib-type="author" id="A5"><name><surname>Cimaz</surname><given-names>Rolando</given-names></name><xref ref-type="aff" rid="I3">3</xref></contrib><contrib contrib-type="author" id="A6"><name><surname>Corona</surname><given-names>Fabrizia</given-names></name><xref ref-type="aff" rid="I4">4</xref></contrib><contrib contrib-type="author" id="A7"><name><surname>Conti</surname><given-names>Giovanni</given-names></name><xref ref-type="aff" rid="I5">5</xref></contrib><contrib contrib-type="author" id="A8"><name><surname>Lepore</surname><given-names>Loredana</given-names></name><xref ref-type="aff" rid="I6">6</xref></contrib><contrib contrib-type="author" id="A9"><name><surname>Olivieri</surname><given-names>Alma Nunzia</given-names></name><xref ref-type="aff" rid="I7">7</xref></contrib><contrib contrib-type="author" id="A10"><name><surname>Rigante</surname><given-names>Donato</given-names></name><xref ref-type="aff" rid="I8">8</xref></contrib><contrib contrib-type="author" id="A11"><name><surname>La Torre</surname><given-names>Francesco</given-names></name><xref ref-type="aff" rid="I9">9</xref></contrib><contrib contrib-type="author" id="A12"><name><surname>Breda</surname><given-names>Luciana</given-names></name><xref ref-type="aff" rid="I10">10</xref></contrib><contrib contrib-type="author" id="A13"><name><surname>Civino</surname><given-names>Adele</given-names></name><xref ref-type="aff" rid="I11">11</xref></contrib><contrib contrib-type="author" id="A14"><name><surname>D'Angelo</surname><given-names>Gianfranco</given-names></name><xref ref-type="aff" rid="I12">12</xref></contrib><contrib contrib-type="author" id="A15"><name><surname>Barone</surname><given-names>Patrizia</given-names></name><xref ref-type="aff" rid="I13">13</xref></contrib><contrib contrib-type="author" id="A16"><name><surname>Consolini</surname><given-names>Rita</given-names></name><xref ref-type="aff" rid="I14">14</xref></contrib><contrib contrib-type="author" id="A17"><name><surname>Gallizzi</surname><given-names>Romina</given-names></name><xref ref-type="aff" rid="I15">15</xref></contrib><contrib contrib-type="author" id="A18"><name><surname>Maggio</surname><given-names>Maria Cristina</given-names></name><xref ref-type="aff" rid="I16">16</xref></contrib><contrib contrib-type="author" id="A19"><name><surname>Alpigiani</surname><given-names>Maria Giannina</given-names></name><xref ref-type="aff" rid="I1">1</xref></contrib><contrib contrib-type="author" id="A20"><name><surname>Martini</surname><given-names>Alberto</given-names></name><xref ref-type="aff" rid="I1">1</xref><xref ref-type="aff" rid="I17">17</xref></contrib><contrib contrib-type="author" id="A21"><name><surname>Ravelli</surname><given-names>Angelo</given-names></name><xref ref-type="aff" rid="I1">1</xref><xref ref-type="aff" rid="I17">17</xref></contrib></contrib-group><aff id="I1"><label>1</label>Istituto G Gaslini, Genova, Italy</aff><aff id="I2"><label>2</label>Ospedale Bambin Ges&#x000f9;, Roma, Italy</aff><aff id="I3"><label>3</label>Az.Ospedaliera-Universitaria Meyer, Firenze, Italy</aff><aff id="I4"><label>4</label>IRCCS Ca' Granda-Ospedale Maggiore Policlinico, Milano, Italy</aff><aff id="I5"><label>5</label>Policlinico di Messina, Messina, Italy</aff><aff id="I6"><label>6</label>IRCCS Burlo Garofalo, Trieste, Italy</aff><aff id="I7"><label>7</label>Seconda Universit&#x000e0; degli Studi di Napoli, Napoli, Italy</aff><aff id="I8"><label>8</label>Policlinico Gemelli, Roma, Italy</aff><aff id="I9"><label>9</label>Ospedale Perrino, Brindisi, Italy</aff><aff id="I10"><label>10</label>Policlinico-Universit&#x000e0; di Chieti, Chieti, Italy</aff><aff id="I11"><label>11</label>Az. Ospedaliera di Tricase, Tricase, Italy</aff><aff id="I12"><label>12</label>Az. Ospedaliera delle Marche, Ancona, Italy</aff><aff id="I13"><label>13</label>Policlinico-Universit&#x000e0; di Catania, Catania, Italy</aff><aff id="I14"><label>14</label>Ospedale Santa Chiara,Universit&#x000e0; di Pisa, Pisa, Italy</aff><aff id="I15"><label>15</label>Universit&#x000e0; di Messina, Messina, Italy</aff><aff id="I16"><label>16</label>Ospedale dei Bambini, Palermo, Italy</aff><aff id="I17"><label>17</label>Universit&#x000e0; di Genova, Genova, Italy</aff><pub-date pub-type="collection"><year>2014</year></pub-date><pub-date pub-type="epub"><day>17</day><month>9</month><year>2014</year></pub-date><volume>12</volume><issue>Suppl 1</issue><supplement><named-content content-type="supplement-title">Proceedings of the 21st European Pediatric Rheumatology (PReS) Congress</named-content><named-content content-type="supplement-sponsor">The publication charges for this supplement were funded by the PReS 2014 congress.</named-content></supplement><fpage>P130</fpage><lpage>P130</lpage><permissions><copyright-statement>Copyright &#x000a9; 2014 Verazza et al; licensee BioMed Central Ltd.</copyright-statement><copyright-year>2014</copyright-year><copyright-holder>Verazza et al; licensee BioMed Central Ltd.</copyright-holder><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/4.0"><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0">http://creativecommons.org/licenses/by/4.0</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated.</license-p></license></permissions><self-uri xlink:href="http://www.ped-rheum.com/content/12/S1/P130"/><conference><conf-date>17-21 September 2014</conf-date><conf-name>21st European Pediatric Rheumatology (PReS) Congress</conf-name><conf-loc>Belgrade, Serbia</conf-loc></conference></article-meta></front><body><sec sec-type="intro"><title>Introduction</title><p>The advent of biologic medications has considerably increased the potential for treatment benefit in juvenile idiopathic arthritis (JIA), with clinical remission being now achievable in a substantial proportion of patients.</p></sec><sec><title>Objectives</title><p>To evaluate the outcome of etanercept (ETN) therapy in Italian children with JIA.</p></sec><sec sec-type="methods"><title>Methods</title><p>This is a multicenter, observational study that includes all children with JIA who were given ETN at Italian pediatric rheumatology centers after January 2000. Patients were classified in 2 groups: Group 1: patients who were no longer taking ETN at study start; Group 2: patients who were still receiving ETN at study start. Patients in Group 1 underwent only retrospective assessments, whereas patients in Group 2 underwent both retrospective and cross-sectional assessments. The primary outcome of the study were reasons for ETN discontinuation in patients in Group 1, and achievement of the states of inactive disease (ID), minimal disease activity (MDA) and parent- and child-acceptable symptom state (PASS, CASS) in patients in Group 2. The above states were assessed through both formal definitions and JADAS cutoffs. The secondary outcome was the evaluation of frequency and characteristics of ETN-related side effects.</p></sec><sec sec-type="results"><title>Results</title><p>Twenty-five centers were asked to make a census of all patients followed at the center who met the inclusion criteria for Group 1 or Group 2. A total of 1230 patients were included in the census. Of these patients, 624 were still receiving ETN (Group 2), whereas 606 had discontinued ETN (Group 1). So far, the data of 772 patients (448 in Group 1 and 324 in Group 2) have been collected. Among the 448 patients in Group 1, reasons for ETN discontinuation included disease remission (57.1%), lack of efficacy (25.5%), and side effects (14.9%). The results of assessment of disease state through formal definitions in 305 children of the 324 children in Group 2 who had already undergone the cross-sectional evaluation were the following: ID 42.2%, MDA 63.8%, PASS 80.9%, CASS 76.7%. The percentages of patients who reached the same disease states assessed through JADAS cutoffs were: ID 45.7%, MDA 62.5%, PASS 71.1%, CASS 67.4%. Serious adverse events were seen in 10 of the 772 patients and included inflammatory bowel disease (4 pts), tuberculosis (1 pt), CMV hepatitis (1 pt), varicella complicated by bronchopneumonia (1 pt), bladder carcinoma (1pt), thyroid carcinoma (1 pt); 1 patient died of streptococcal sepsis.</p></sec><sec sec-type="conclusions"><title>Conclusion</title><p>A substantial proportion of children currently receiving ETN were in the states of ID or MDA, or were satisfied with treatment outcome. More than half of the patients who had been discontinued from ETN before study start had the medication stopped because of disease remission. Serious adverse events were uncommon.</p></sec><sec><title>Disclosure of interest</title><p>None declared.</p></sec></body></article>